ATE464320T1 - Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) - Google Patents

Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)

Info

Publication number
ATE464320T1
ATE464320T1 AT02758350T AT02758350T ATE464320T1 AT E464320 T1 ATE464320 T1 AT E464320T1 AT 02758350 T AT02758350 T AT 02758350T AT 02758350 T AT02758350 T AT 02758350T AT E464320 T1 ATE464320 T1 AT E464320T1
Authority
AT
Austria
Prior art keywords
ntb
activity
natural killer
killer cells
implied
Prior art date
Application number
AT02758350T
Other languages
German (de)
English (en)
Inventor
Alessandro Moretta
Cristina Bottino
Roberto Biassoni
Original Assignee
Innate Pharma
Univ Genova
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innate Pharma, Univ Genova filed Critical Innate Pharma
Application granted granted Critical
Publication of ATE464320T1 publication Critical patent/ATE464320T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
AT02758350T 2001-07-19 2002-07-17 Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk) ATE464320T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01401946 2001-07-19
PCT/EP2002/007945 WO2003008449A1 (en) 2001-07-19 2002-07-17 Ntb-a, a surface molecule involved in natural killer cells activity

Publications (1)

Publication Number Publication Date
ATE464320T1 true ATE464320T1 (de) 2010-04-15

Family

ID=8182813

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02758350T ATE464320T1 (de) 2001-07-19 2002-07-17 Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)

Country Status (8)

Country Link
US (2) US7138243B2 (enExample)
EP (1) EP1406928B1 (enExample)
JP (1) JP4326944B2 (enExample)
AT (1) ATE464320T1 (enExample)
AU (1) AU2002325333B2 (enExample)
CA (1) CA2454185A1 (enExample)
DE (1) DE60235985D1 (enExample)
WO (1) WO2003008449A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04001986A (es) * 2001-08-29 2004-06-07 Genentech Inc Composiciones y metodos para el tratamiento de enfermedades relacionadas a la inmunidad.
RU2481356C2 (ru) 2004-12-28 2013-05-10 Иннейт Фарма Моноклональные антитела против nkg2a
DK2038306T3 (en) 2006-06-30 2015-03-09 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
TW200823237A (en) * 2006-08-28 2008-06-01 Nuvelo Inc Antibodies to NTB-A
MX2010007935A (es) 2008-01-24 2010-08-23 Novo Nordisk As Anticuerpo monoclonal humanizado anti-nkg2a humano.
MX342131B (es) 2011-06-17 2016-09-14 Novo Nordisk As Eliminacion selectiva de celulas erosivas.
WO2014100740A1 (en) * 2012-12-21 2014-06-26 Seattle Genetics, Inc. Anti-ntb-a antibodies and related compositions and methods
US10344073B2 (en) 2014-01-09 2019-07-09 Hadasit Medical Research Services And Development Ltd. Cell compositions and methods for cancer therapy
EP3325967B1 (en) 2015-07-24 2019-12-04 Innate Pharma Methods for detecting tissue infiltrating nk cells
WO2019126736A1 (en) * 2017-12-21 2019-06-27 New York University Pd-1 related cancer therapy
JP7458318B2 (ja) 2018-02-12 2024-03-29 ハダシット メディカル リサーチ サービシーズ アンド ディベロップメント リミテッド 癌治療のためのｓｌａｍｆ６スプライスバリアントの調節
IL267614A (en) 2019-06-24 2019-09-26 Lotem Michal Nucleic acids to modulate SLAMF6 isoforms
EP4163367A4 (en) * 2020-06-09 2024-06-26 Samsung Life Public Welfare Foundation GENETICALLY MANIPULATED CELL STRAIN FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF
CN116179488A (zh) * 2023-03-09 2023-05-30 广东唯泰生物科技有限公司 外周血自然杀伤细胞的体外扩增方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4337197C1 (de) * 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
JP2003521903A (ja) * 2000-01-25 2003-07-22 ハイセック，インコーポレーテッド Ｃｄ８４様ポリペプチドおよびポリヌクレオチドに関する方法と材料
US7029677B2 (en) 2000-01-25 2006-04-18 Nuvelo, Inc. Methods of therapy and diagnosis using immunotargeting of CD84Hy1-expressing cells
AU2001274888A1 (en) * 2000-05-19 2001-12-03 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
CA2421056A1 (en) * 2000-09-01 2002-03-28 Genentech, Inc. A polypeptide for use as a diagnostic marker for the presence of colon tumours
EP1223218A1 (en) * 2000-11-03 2002-07-17 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules and uses thereof
US20030180888A1 (en) 2000-11-03 2003-09-25 Millennium Pharmaceuticals, Inc. CD2000 and CD2001 molecules, and uses thereof
WO2002077173A2 (en) * 2001-03-22 2002-10-03 Bristol-Myers Squibb Company Polynucleotide encoding a novel immunoglobulin superfamily member, apex4, and variants and splice variants thereof

Also Published As

Publication number Publication date
DE60235985D1 (de) 2010-05-27
EP1406928A1 (en) 2004-04-14
US7138243B2 (en) 2006-11-21
US20070065875A1 (en) 2007-03-22
WO2003008449A1 (en) 2003-01-30
WO2003008449A8 (en) 2004-02-26
AU2002325333B2 (en) 2008-04-03
US20050159332A1 (en) 2005-07-21
CA2454185A1 (en) 2003-01-30
JP4326944B2 (ja) 2009-09-09
JP2005507648A (ja) 2005-03-24
EP1406928B1 (en) 2010-04-14

Similar Documents

Publication Publication Date Title
DE60235985D1 (de) Ntb-a, ein oberflächenmolekül impliziert in der aktivität natürlicher killerzellen (nk)
WO2002031134A3 (en) Novel serine protease genes related to dppiv
ATE342359T1 (de) Design von beta-faltblatt-proteinen mit spezifischen bindungseigenschaften
DE602005011486D1 (de) Säure-pilzprotease bei der fermentation von nichtlöslichen stärkesubstraten
DE60144145D1 (de) Subtilisin-variante
ATE319818T1 (de) Polypeptide mit aminopeptidaseaktivität und für diese kodierende nukleinsäuren
BR0011499A (pt) Moléculas de ácido nucléico oriundas de plantas e células de,planta transgênicas de trigo e o seu uso para a produção de amido modificado
DK1294876T3 (da) EV-VEGF-nukleinsyrer og -polypeptider samt fremgangsmåder til deres benyttelse
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
MX2010003055A (es) Nuevas citocinas aviares y secuencias geneticas que las codifican.
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
ATE500266T1 (de) Methode zur verbesserung der wirksamkeit von biologischen antwort-verändernden proteinen und exemplarische muteine
DE69837475D1 (de) Polypeptide mit aminopeptidaseaktivität und dafür kodierende nukleinsäuren
ATE311443T1 (de) Methoden zur durchforstung (screenen) von proteinen
WO2004042083A3 (en) Nucleic acid ligands and uses therefor
BR0212070A (pt) ácidos nucléicos e polipeptìdeos bv8 com atividade mitogênica
DE60139113D1 (de) 18477, eine menschliche proteinkinase und deren verwendung
DK1379639T3 (da) Muse-glucuronyl-C5-epimerase, DNA der koder for samme, og anvendelser deraf
DE60040077D1 (de) Vermehrungsproteine von pflanzen
AU5166200A (en) Human tumor necrosis factor receptor tr10
WO2004029276A3 (en) Nucleic acids encoding a mammalian raptor polypeptide and uses therefor
DK1233980T3 (da) Nukleinsyremolekyle, omfattende en nukleinsyresekvens, der koder for et hæmocyanin, og mindst en intronsekvens
WO2001079525A3 (en) Purified and isolated potassium-chloride cotransporter nucleic acids and polypeptides and therapeutic and screening methods using same
KR20040053279A (ko) 스트레스 저항성 및 내성 단백질을 코딩하는 유전자
ATE423200T1 (de) Neues plexin-polypeptid, dieses codierende dna und verwendung davon

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties